Asthma is among the most prevalent chronic respiratory conditions worldwide, characterized by airway hyperresponsiveness, chronic bronchial inflammation, and variable airflow obstruction. you can try these out While the vast majority of individuals with asthma achieve symptom control through low-to-medium-dose inhaled corticosteroids (ICS) combined with long-acting β2-agonists (LABA), a distinct subset—approximately 5% to 10% of the global asthma population—suffers from severe asthma.
According to global consensus guidelines from the Global Initiative for Asthma (GINA) and the European Respiratory Society / American Thoracic Society (ERS/ATS), severe asthma is defined as asthma that remains uncontrolled despite optimized high-dose ICS-LABA therapy and management of modifiable factors (such as inhaler technique, adherence, and comorbidities), or that requires high-dose therapy to maintain control. Patients with severe asthma experience frequent exacerbations, progressive lung function decline, heightened risk of corticosteroid-induced adverse effects, and substantial impairment in daily quality of life.
Inflammatory Endotypes: T2-High vs. Non-T2 / T2-Low
Modern respiratory medicine has shifted from viewing severe asthma as a single uniform disease to recognizing it as a heterogeneous group of disorders defined by specific molecular mechanisms (endotypes) and observable clinical characteristics (phenotypes).
[ Severe Asthma Endotypes ]
│
┌──────────────────────────────────┴──────────────────────────────────┐
▼ ▼
[ Type 2 High (T2-High) Inflammation ] [ Non-T2 / T2-Low Inflammation ]
• Driven by Eosinophils, IgE, IL-4, IL-5, & IL-13 • Driven by Neutrophils, IL-17, & Structural Changes
• High blood/sputum eosinophils & elevated FeNO • Paucigranulocytic or Neutrophilic infiltration
• Highly responsive to targeted biologics • Often corticosteroid-resistant
1. Type 2 High (T2-High) Severe Asthma
Characterized by prominent eosinophilic airway inflammation and allergic sensitization, driven by two primary pathways:
- Allergic Cascade: Inhaled allergens activate dendritic cells, presenting antigens to naive T-cells and promoting differentiation into T-helper 2 (Th2\text{Th2}Th2) cells. These cells secrete key cytokines:
- Interleukin-4 (IL-4\text{IL-4}IL-4) and Interleukin-13 (IL-13\text{IL-13}IL-13): Induce B-cell class switching to produce Immunoglobulin E (IgE\text{IgE}IgE) and drive bronchial hyperresponsiveness, mucus hypersecretion, and airway remodeling.
- Interleukin-5 (IL-5\text{IL-5}IL-5): The key growth factor responsible for eosinophil differentiation, recruitment, activation, and survival in bone marrow and airway tissues.
- Non-Allergic (Eosinophilic) Cascade: Environmental pollutants, viral infections, or airborne irritants stimulate airway epithelial cells to release alarmins—such as TSLP (Thymic Stromal Lymphopoietin), IL-33, and IL-25. These alarmins activate Group 2 Innate Lymphoid Cells (ILC2s), which produce high volumes of IL-5 and IL-13 independent of IgE or specific allergen sensitization.
2. Non-Type 2 (T2-Low) Severe Asthma
Less understood and notoriously difficult to treat, T2-Low asthma features a predominance of neutrophils or a lack of granulocytic infiltration (paucigranulocytic asthma). Driven by Th17\text{Th17}Th17 cell activation, Interleukin-17 (IL-17), oxidative stress, systemic metabolic dysfunction (e.g., obesity-associated asthma), and cigarette smoke exposure, T2-Low asthma displays poor responsiveness to inhaled and oral corticosteroids.
Biomarkers for Endotypic Stratification
Directing precision therapy in severe asthma requires measuring see here now key clinical biomarkers to identify the underlying inflammatory endotype:
| Biomarker | Physiological Basis | Clinical Utility & Target Cut-offs |
|---|---|---|
| Blood Eosinophil Count (BEC) | Reflects systemic and airway eosinophilic inflammation driven by IL-5. | Counts ≥150–300 cells/μL indicate T2-high inflammation; guides anti-IL-5/5R biologic selection. |
| Fractional Exhaled Nitric Oxide (FeNO) | Measures inducible nitric oxide synthase (iNOS) activity in airway epithelium, upregulated by IL-13. | Levels ≥20–25 ppb indicate active IL-13-driven T2 inflammation and steroid responsiveness. |
| Serum Total and Specific IgE | Quantifies allergic sensitization and circulating reaginic antibodies. | Elevated serum IgE combined with perennial allergen sensitization guides anti-IgE biologic therapy. |
| Sputum Eosinophils / Neutrophils | Direct assessment of inflammatory cell populations in induced lower airway secretions. | Sputum eosinophils >2% confirm eosinophilic asthma; high sputum neutrophils suggest T2-low phenotype. |
Stepwise Management and Targeted Biologic Therapies
Managing severe asthma follows a structured evaluation framework: confirming the diagnosis, ruling out alternative conditions (such as vocal cord dysfunction or bronchiectasis), optimizing inhaler compliance, treating co-existing comorbidities (e.g., chronic rhinosinusitis with nasal polyps, GERD, obstructive sleep apnea), and escalating to targeted biologic therapy.
[ Uncontrolled High-Dose ICS-LABA Asthma ]
│
▼
[ Systematic Assessment: Adherence, Technique, & Comorbidities ]
│
▼
[ Biomarker Phenotyping (BEC, FeNO, IgE) ]
│
┌─────────────────────────────┴─────────────────────────────┐
▼ ▼
[ T2-High Phenotype Identified ] [ T2-Low Phenotype Identified ]
• Initiate Add-on Targeted Biologic • High-Dose ICS-LABA + LAMA (Tiotropium)
• Anti-IgE, Anti-IL5/5R, Anti-IL4R, or Anti-TSLP • Trial of Macrolides (Azithromycin)
• Bronchial Thermoplasty Consideration
1. Targeted Biologic Therapies for T2-High Severe Asthma
Biologic agents targeting specific cytokines and receptors have revolutionized severe asthma management, dramatically reducing oral corticosteroid dependence and exacerbation rates:
- Anti-IgE Therapy (Omalizumab): Humanized monoclonal antibody that binds free circulating IgE, preventing its binding to high-affinity FcϵRI receptors on mast cells and basophils. Indicated for severe allergic asthma with elevated serum IgE and positive perennial allergen testing.
- Anti-IL-5 / Anti-IL-5 Receptor Therapies (Mepolizumab, Reslizumab, Benralizumab):
- Mepolizumab & Reslizumab: Bind directly to the IL-5 ligand, preventing it from binding to the IL-5 receptor α subunit.
- Benralizumab: Binds directly to the IL-5R$\alpha$ receptor on eosinophils and recruits natural killer (NK) cells to induce rapid, near-complete antibody-dependent cell-mediated cytotoxicity (ADCC) eosinophil depletion.
- Anti-IL-4R$\alpha$ Therapy (Dupilumab): Monoclonal antibody targeting the shared IL-4R$\alpha$ subunit, simultaneously blocking both IL-4 and IL-13 signaling. Highly effective in reducing exacerbations, improving FEV1, and treating co-morbid atopic dermatitis and chronic rhinosinusitis with nasal polyps.
- Anti-TSLP Therapy (Tezepelumab): A first-in-class biologic targeting Thymic Stromal Lymphopoietin (TSLP), an upstream epithelial alarmin. By blocking TSLP at the top of the inflammatory cascade, tezepelumab reduces exacerbations across both T2-High and T2-Low severe asthma populations.
2. Management Strategies for T2-Low Severe Asthma
For patients lacking T2 inflammatory markers:
- Add-On Long-Acting Muscarinic Antagonists (LAMA): Tiotropium provides additional bronchodilation via M3 muscarinic receptor blockade.
- Low-Dose Macrolide Therapy: Long-term low-dose azithromycin exerts non-antibiotic immunomodulatory effects, reducing neutrophilic inflammation and exacerbation frequency.
- Bronchial Thermoplasty: A non-pharmacological interventional procedure delivering radiofrequency thermal energy to bronchial walls during bronchoscopy, reducing smooth muscle mass and airway hyperresponsiveness.
Conclusion
Severe asthma is a complex disease driven by distinct inflammatory endotypes. By utilizing clinical biomarkers—such as blood eosinophil counts, FeNO, and serum IgE—clinicians can categorize patients into T2-high or T2-low phenotypes and deploy targeted therapies. Biologic agents directed against IgE, IL-5, IL-4/IL-13, Get the facts and upstream epithelial alarmins like TSLP allow healthcare teams to achieve disease control, improve lung function, and reduce dependence on systemic corticosteroids.